Abstract Details

Title Reliability of Remote Virtual Administration of the Symbol Digit Modalities Test to Individuals with Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 038

Objective This study examined the reliability of remote administration of the SDMT through a virtual telehealth platform to individuals with MS.

Background The Symbol Digit Modalities Test (SDMT) is the gold standard in screening for cognitive involvement in multiple sclerosis (MS), and is often used in the outpatient setting. Due to the recent COVID-19 pandemic, many patients underwent clinical visits with their providers via telehealth platforms for assessment and monitoring of disease progression, with considerable concerns for validity and reliability of findings.

Design/Methods We tested reliability between an in-person and a virtual administration of the SDMT (oral administration). Participants with confirmed MS were enrolled in a clinical trial of a cognitive remediation program. Participants were prescreened with a virtual administration of the SDMT in advance of the in-person baseline study visit, where an alternate SDMT form was administered according to standard procedures.

Results Data for n = 134 participants (age = 49.7, range 18 to 69 years; median EDSS = 2.0, range 1.0 to 3.0) were available for analysis. Virtual and in-person SDMT scores were strongly correlated (r = .81, p = .000).

Conclusions Remote administration of the SDMT through a virtual platform is a feasible and reliable cognitive screening approach for individuals with MS.

Authors/Disclosures
Tehila Eilam-Stock, PhD (NYU Langone Health) PRESENTER	Dr. Eilam-Stock has nothing to disclose.
Michael Shaw	Mr. Shaw has nothing to disclose.
Kathleen Sherman (NYU Langone Health, MS Comprehensive Care Center)	An immediate family member of Ms. Sherman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Total Solutions. An immediate family member of Ms. Sherman has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for APA.
Lauren B. Krupp, MD, FAAN (NYU Langone Medical Center)	Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EBIX. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman LaRoche. Dr. krupp has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for MMMK. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Patrick, Dolan, and Kaufman. Dr. krupp has received intellectual property interests from a discovery or technology relating to health care.
Leigh E. Charvet, PhD (NYU Langone)	Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Johnson & Johnson. Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Springer Healthcare. Dr. Charvet has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for YBrain. Dr. Charvet has stock in Johnson&Johnson.

��ɫ��

��ɫ��